EA031488B1 - Способ лечения гинекологических заболеваний - Google Patents
Способ лечения гинекологических заболеваний Download PDFInfo
- Publication number
- EA031488B1 EA031488B1 EA201491614A EA201491614A EA031488B1 EA 031488 B1 EA031488 B1 EA 031488B1 EA 201491614 A EA201491614 A EA 201491614A EA 201491614 A EA201491614 A EA 201491614A EA 031488 B1 EA031488 B1 EA 031488B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cdb
- administration
- vaginal
- pharmaceutical composition
- week
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 112
- 239000002207 metabolite Substances 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 239000006213 vaginal ring Substances 0.000 claims abstract description 50
- 229940044953 vaginal ring Drugs 0.000 claims abstract description 45
- OOLLAFOLCSJHRE-HCPABCRVSA-N [(13s,17r)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC(N(C)C)=CC=C1C1C2=C3CCC(=O)C=C3CCC2C(CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-HCPABCRVSA-N 0.000 claims abstract description 32
- 208000024891 symptom Diseases 0.000 claims abstract description 23
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 186
- 239000002379 progesterone receptor modulator Substances 0.000 claims description 76
- 102000003998 progesterone receptors Human genes 0.000 claims description 47
- 108090000468 progesterone receptors Proteins 0.000 claims description 47
- 201000010260 leiomyoma Diseases 0.000 claims description 42
- 229960000499 ulipristal acetate Drugs 0.000 claims description 34
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 31
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 22
- 208000032843 Hemorrhage Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 210000004696 endometrium Anatomy 0.000 claims description 17
- 230000000740 bleeding effect Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 201000009273 Endometriosis Diseases 0.000 claims description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 12
- 210000004291 uterus Anatomy 0.000 claims description 12
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 11
- 230000002357 endometrial effect Effects 0.000 claims description 11
- 208000037853 Abnormal uterine bleeding Diseases 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 10
- 208000005641 Adenomyosis Diseases 0.000 claims description 8
- 238000011260 co-administration Methods 0.000 claims description 8
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 8
- 201000004458 Myoma Diseases 0.000 claims description 7
- 239000000186 progesterone Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 claims description 6
- 206010016629 fibroma Diseases 0.000 claims description 5
- 230000005906 menstruation Effects 0.000 claims description 5
- 210000000754 myometrium Anatomy 0.000 claims description 5
- 201000007954 uterine fibroid Diseases 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000583 progesterone congener Substances 0.000 claims description 4
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000009435 amidation Effects 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000006240 deamidation Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- HKDLNTKNLJPAIY-DWWOYTEKSA-N (8s,13s,14s,17r)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1C1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-DWWOYTEKSA-N 0.000 claims 32
- 239000003826 tablet Substances 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 12
- 229960000200 ulipristal Drugs 0.000 claims 11
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 9
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 9
- 230000000875 corresponding effect Effects 0.000 claims 9
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 9
- 239000004814 polyurethane Substances 0.000 claims 9
- 239000002775 capsule Substances 0.000 claims 8
- 229920002635 polyurethane Polymers 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 235000019359 magnesium stearate Nutrition 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 6
- -1 19proprogesterone Chemical class 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- 235000012222 talc Nutrition 0.000 claims 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 108010010803 Gelatin Proteins 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- 206010046910 Vaginal haemorrhage Diseases 0.000 claims 4
- 239000002585 base Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000007891 compressed tablet Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008273 gelatin Substances 0.000 claims 4
- 229920000159 gelatin Polymers 0.000 claims 4
- 235000019322 gelatine Nutrition 0.000 claims 4
- 235000011852 gelatine desserts Nutrition 0.000 claims 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 239000007909 solid dosage form Substances 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- 206010062767 Hypophysitis Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008298 dragée Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000007937 lozenge Substances 0.000 claims 3
- 150000003961 organosilicon compounds Chemical class 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 210000003635 pituitary gland Anatomy 0.000 claims 3
- 229920001296 polysiloxane Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000000829 suppository Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 229920001817 Agar Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 206010014756 Endometrial hypertrophy Diseases 0.000 claims 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 2
- 241000206672 Gelidium Species 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 150000008043 acidic salts Chemical class 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 235000010419 agar Nutrition 0.000 claims 2
- 150000001447 alkali salts Chemical class 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 239000000440 bentonite Substances 0.000 claims 2
- 229910000278 bentonite Inorganic materials 0.000 claims 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000007907 direct compression Methods 0.000 claims 2
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 230000000670 limiting effect Effects 0.000 claims 2
- 229940040129 luteinizing hormone Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 230000008092 positive effect Effects 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 240000003183 Manihot esculenta Species 0.000 claims 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000002595 Solanum tuberosum Nutrition 0.000 claims 1
- 244000061456 Solanum tuberosum Species 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000003655 absorption accelerator Substances 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000011575 calcium Chemical class 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000013013 elastic material Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Chemical class 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 1
- 230000036732 histological change Effects 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 229940060367 inert ingredients Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000012907 medicinal substance Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000002175 menstrual effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920003225 polyurethane elastomer Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000011591 potassium Chemical class 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 239000012254 powdered material Substances 0.000 claims 1
- 210000003689 pubic bone Anatomy 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 239000003340 retarding agent Substances 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229910052709 silver Chemical class 0.000 claims 1
- 239000004332 silver Chemical class 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 238000010561 standard procedure Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 claims 1
- 229940044959 vaginal cream Drugs 0.000 claims 1
- 239000000259 vaginal foam Substances 0.000 claims 1
- 239000000029 vaginal gel Substances 0.000 claims 1
- 229940098946 vaginal ointment Drugs 0.000 claims 1
- 239000006216 vaginal suppository Substances 0.000 claims 1
- 239000000003 vaginal tablet Substances 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- 206010027514 Metrorrhagia Diseases 0.000 description 8
- 230000001850 reproductive effect Effects 0.000 description 8
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 4
- 229940046085 endocrine therapy drug gonadotropin releasing hormone analogues Drugs 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 208000000450 Pelvic Pain Diseases 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002632 myometrial effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000685 uterine artery Anatomy 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010027295 Menometrorrhagia Diseases 0.000 description 1
- 206010033314 Ovulation pain Diseases 0.000 description 1
- 208000034424 Painful defaecation Diseases 0.000 description 1
- 206010046782 Uterine enlargement Diseases 0.000 description 1
- 206010067269 Uterine fibrosis Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614785P | 2012-03-23 | 2012-03-23 | |
| EP12160956.4A EP2641602A1 (en) | 2012-03-23 | 2012-03-23 | Method for treating gynecological diseases |
| PCT/IB2013/052274 WO2013140372A1 (en) | 2012-03-23 | 2013-03-22 | Method for treating gynecological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491614A1 EA201491614A1 (ru) | 2015-01-30 |
| EA031488B1 true EA031488B1 (ru) | 2019-01-31 |
Family
ID=45976689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491614A EA031488B1 (ru) | 2012-03-23 | 2013-03-22 | Способ лечения гинекологических заболеваний |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10441534B2 (enExample) |
| EP (3) | EP2641602A1 (enExample) |
| JP (2) | JP2015514700A (enExample) |
| KR (1) | KR20140138824A (enExample) |
| CN (1) | CN104203246A (enExample) |
| AU (1) | AU2013236960B2 (enExample) |
| CA (1) | CA2864073A1 (enExample) |
| CO (1) | CO7111317A2 (enExample) |
| EA (1) | EA031488B1 (enExample) |
| GE (1) | GEP201706696B (enExample) |
| HK (1) | HK1199827A1 (enExample) |
| MX (1) | MX369520B (enExample) |
| MY (1) | MY172530A (enExample) |
| NZ (1) | NZ630011A (enExample) |
| SG (1) | SG11201404921QA (enExample) |
| TW (2) | TW201400121A (enExample) |
| WO (1) | WO2013140372A1 (enExample) |
| ZA (1) | ZA201407575B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112909A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017112904A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| JP6906525B2 (ja) | 2015-12-23 | 2021-07-21 | オリック ファーマシューティカルズ，インク． | グルココルチコイド受容体の阻害剤 |
| WO2017165707A1 (en) * | 2016-03-24 | 2017-09-28 | Juniper Pharmaceuticals, Inc. | Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures |
| CN110099915A (zh) | 2016-10-07 | 2019-08-06 | 欧瑞克制药公司 | 糖皮质激素受体抑制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009095418A1 (en) * | 2008-01-29 | 2009-08-06 | Erin Gainer | Use of ulipristal for treating uterine fibroids |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3545439A (en) | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
| US3920805A (en) | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
| IL48277A (en) | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
| US4155991A (en) | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
| US3991760A (en) | 1975-12-02 | 1976-11-16 | The Procter & Gamble Company | Vaginal medicament dispensing means |
| US3995634A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal cavity dispensing means and method |
| US3995633A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal Medicament dispensing device |
| US4286587A (en) | 1978-10-11 | 1981-09-01 | Alza Corporation | Vaginal drug delivery system made from polymer |
| US4292965A (en) | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| US4250611A (en) | 1979-04-19 | 1981-02-17 | Alza Corporation | Process for making drug delivery device with reservoir |
| US4596576A (en) | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
| NL8500470A (nl) | 1985-02-19 | 1986-09-16 | Achel Homesteel Pvba | Intravaginaal orgaan. |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| FI95768C (fi) | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
| US5929262A (en) | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
| ES2212912B1 (es) | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
| US20060111577A1 (en) | 2003-02-28 | 2006-05-25 | Kim Hyun K | Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
| KR101229701B1 (ko) | 2004-07-09 | 2013-02-05 | 라보라토이레 에이치알에이 파르마 | 프로게스테론 수용체 조절제를 함유하는 서방형 조성물 |
| US8569274B2 (en) * | 2007-04-20 | 2013-10-29 | Preglem S.A. | Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding |
| LT2249757T (lt) * | 2008-02-04 | 2017-09-25 | Ferring B.V. | Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai |
-
2012
- 2012-03-23 EP EP12160956.4A patent/EP2641602A1/en not_active Withdrawn
-
2013
- 2013-03-22 EP EP17192417.8A patent/EP3363500A1/en not_active Withdrawn
- 2013-03-22 TW TW102110291A patent/TW201400121A/zh unknown
- 2013-03-22 MX MX2014011487A patent/MX369520B/es active IP Right Grant
- 2013-03-22 NZ NZ630011A patent/NZ630011A/en not_active IP Right Cessation
- 2013-03-22 KR KR1020147027575A patent/KR20140138824A/ko not_active Ceased
- 2013-03-22 AU AU2013236960A patent/AU2013236960B2/en not_active Ceased
- 2013-03-22 HK HK15100309.9A patent/HK1199827A1/xx unknown
- 2013-03-22 US US14/386,726 patent/US10441534B2/en not_active Expired - Fee Related
- 2013-03-22 CA CA2864073A patent/CA2864073A1/en not_active Abandoned
- 2013-03-22 GE GEAP201313608A patent/GEP201706696B/en unknown
- 2013-03-22 EA EA201491614A patent/EA031488B1/ru not_active IP Right Cessation
- 2013-03-22 TW TW107104368A patent/TW201832767A/zh unknown
- 2013-03-22 EP EP13721095.1A patent/EP2827873A1/en not_active Ceased
- 2013-03-22 WO PCT/IB2013/052274 patent/WO2013140372A1/en not_active Ceased
- 2013-03-22 CN CN201380014168.1A patent/CN104203246A/zh active Pending
- 2013-03-22 SG SG11201404921QA patent/SG11201404921QA/en unknown
- 2013-03-22 MY MYPI2014002228A patent/MY172530A/en unknown
- 2013-03-22 JP JP2015501044A patent/JP2015514700A/ja active Pending
-
2014
- 2014-10-17 ZA ZA2014/07575A patent/ZA201407575B/en unknown
- 2014-10-20 CO CO14231832A patent/CO7111317A2/es unknown
-
2018
- 2018-02-13 JP JP2018023604A patent/JP2018109025A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009095418A1 (en) * | 2008-01-29 | 2009-08-06 | Erin Gainer | Use of ulipristal for treating uterine fibroids |
Non-Patent Citations (5)
| Title |
|---|
| CREATSAS G, HASSAN E, DELIGEOROGLOU E, CHARALAMBIDIS V: "Combined oral and vaginal treatment of severe vulvovaginitis during childhood.", JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 12, no. 1, 12 February 1999 (1999-02-12), AMSTERDAM, NL, pages 23 - 25, XP002676688, ISSN: 1083-3188, DOI: 10.1016/S1083-3188(00)86616-4 * |
| DAVID KMAK, ET AL: "COMPARISON OF ORAL INTRAVAGINAL AND COMBINATION MISOPROSTOL THERAPY FOR SECOND TRIMESTER INDUCTIONS", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 185, no. 6 Supplement, 14 January 2002 (2002-01-14) - 19 January 2002 (2002-01-19), US, pages S205 (451) - S, XP002676687, ISSN: 0002-9378 * |
| DIETZ, A. ; CHUANG, L. ; KLEIN, J. ; COPPERMAN, A.B. ; MUKHERJEE, T.: "Transitioning from intra-muscular progesterone to combination oral and vaginal progesterone supplementation prior to the luteo-placetal shift does not diminish ART success", FERTILITY AND STERILITY., ELSEVIER SCIENCE INC, NEW YORK, NY, USA, vol. 92, no. 3, 1 September 2009 (2009-09-01), USA, pages S60 - S61, XP026543020, ISSN: 0015-0282, DOI: 10.1016/j.fertnstert.2009.07.235 * |
| DONNEZ J, TATARCHUK T F, BOUCHARD P, PUSCASIU L, ZAKHARENKO N F, IVANOVA T, UGOCSAI G, MARA M, JILLA M P, BESTEL E, TERRILL P, OST: "Ulipristal acetate versus placebo for fibroid treatment before surgery.", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 366, no. 5, 2 February 2012 (2012-02-02), US, pages 409 - 420, XP002676689, ISSN: 1533-4406, DOI: 10.1056/NEJMoa1103182 * |
| TOMIC VLATKA; TOMIC JOZO; KLAIC DJURDJA ZIGMUNDOVAC: "Oral micronized progesterone combined with vaginal progesterone gel for luteal support.", GYNECOLOGICAL ENDOCRINOLOGY, TAYLOR & FRANCIS, GB, vol. 27, no. 12, 1 December 2011 (2011-12-01), GB, pages 1010 - 1013, XP009159713, ISSN: 0951-3590, DOI: 10.3109/09513590.2011.569791 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140138824A (ko) | 2014-12-04 |
| CA2864073A1 (en) | 2013-09-26 |
| CN104203246A (zh) | 2014-12-10 |
| AU2013236960B2 (en) | 2017-11-23 |
| TW201832767A (zh) | 2018-09-16 |
| GEP201706696B (en) | 2017-07-10 |
| JP2015514700A (ja) | 2015-05-21 |
| HK1199827A1 (en) | 2015-07-24 |
| MX2014011487A (es) | 2015-01-12 |
| MX369520B (es) | 2019-11-11 |
| TW201400121A (zh) | 2014-01-01 |
| US10441534B2 (en) | 2019-10-15 |
| JP2018109025A (ja) | 2018-07-12 |
| EP2641602A1 (en) | 2013-09-25 |
| CO7111317A2 (es) | 2014-11-10 |
| ZA201407575B (en) | 2015-12-23 |
| NZ630011A (en) | 2016-12-23 |
| US20150038476A1 (en) | 2015-02-05 |
| WO2013140372A1 (en) | 2013-09-26 |
| MY172530A (en) | 2019-11-29 |
| EP2827873A1 (en) | 2015-01-28 |
| AU2013236960A1 (en) | 2014-09-25 |
| SG11201404921QA (en) | 2014-10-30 |
| EA201491614A1 (ru) | 2015-01-30 |
| EP3363500A1 (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5991988B2 (ja) | 子宮内膜基底層の剥脱に関する疼痛の治療 | |
| KR20120044307A (ko) | 긴급 피임용 제약 조성물 | |
| MD3518933T2 (ro) | Metode de tratare a fibromului uterin și endometriozei | |
| JP2018109025A (ja) | 婦人科疾患の治療方法 | |
| US6207696B1 (en) | Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine | |
| CN101917848B (zh) | 用于治疗子宫收缩过强病症的s-烷基异硫脲衍生物 | |
| US20190262361A1 (en) | Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids | |
| EP4406539A1 (en) | Low-dose mifepristone for the treatment of endometriosis associated pain | |
| JP2000159688A (ja) | 子宮内膜症の処置又は予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |